Latest News Story Headlines
2024 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter.
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug.
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Jun 24, 2024
Calendar & Upcoming Events
Webinar: Amyloidosis: Effective Paient-Doctor Communications
Webinar Session, Wednesday, October 2, 2024 at 6 PM (ET)
Webinar: Updates in AL amyloidosis: Fast Forward in 2024!
Webinar: Updates in AL amyloidosis: Fast Forward in 2024!
Speaker: Dr. Heather Landau, MD Memorial Sloan Kettering Cancer Center
Sign Up for the Latest Updates
Get news from Amyloidosis Foundation
in your inbox
By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.